Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Galvani E, et al. Among authors: giovannetti e. Curr Pharm Des. 2013;19(5):818-32. Curr Pharm Des. 2013. PMID: 22973953 Review.
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Galvani E, Giovannetti E, Saccani F, Cavazzoni A, Leon LG, Dekker H, Alfieri R, Carmi C, Mor M, Ardizzoni A, Petronini PG, Peters GJ. Galvani E, et al. Among authors: giovannetti e. Neoplasia. 2013 Jan;15(1):61-72. doi: 10.1593/neo.121434. Neoplasia. 2013. PMID: 23359111 Free PMC article.
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR. La Monica S, et al. Among authors: giovannetti e. PLoS One. 2013 Oct 22;8(10):e78656. doi: 10.1371/journal.pone.0078656. eCollection 2013. PLoS One. 2013. PMID: 24167634 Free PMC article.
c-Met as a Target for Personalized Therapy.
Garajová I, Giovannetti E, Biasco G, Peters GJ. Garajová I, et al. Among authors: giovannetti e. Transl Oncogenomics. 2015 Nov 23;7(Suppl 1):13-31. doi: 10.4137/TOG.S30534. eCollection 2015. Transl Oncogenomics. 2015. PMID: 26628860 Free PMC article. Review.
MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.
Garajová I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, Frassineti GL, Gavelli G, Frampton AE, Biasco G, Giovannetti E. Garajová I, et al. Among authors: giovannetti e. Clin Epigenetics. 2015 Dec 16;7:129. doi: 10.1186/s13148-015-0162-5. eCollection 2015. Clin Epigenetics. 2015. PMID: 26677401 Free PMC article.
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. Caparello C, et al. Among authors: giovannetti e. World J Gastroenterol. 2016 Aug 21;22(31):6987-7005. doi: 10.3748/wjg.v22.i31.6987. World J Gastroenterol. 2016. PMID: 27610011 Free PMC article. Review.
400 results